|
1
|
Tunissiolli NM, Castanhole-Nunes MMU,
Biselli-Chicote PM, Pavarino EC, da Silva RF, da Silva RC and
Goloni-Bertollo EM: Hepatocellular carcinoma: A comprehensive
review of biomarkers, clinical aspects, and therapy. Asian Pac J
Cancer Prev. 18:863–872. 2017.PubMed/NCBI
|
|
2
|
Gao G, Dong F, Xu X, Hu A and Hu Y:
Diagnostic value of serum Golgi protein 73 for HBV-related primary
hepatic carcinoma. Int J Clin Exp Pathol. 8:11379–11385.
2015.PubMed/NCBI
|
|
3
|
Ismail MM, Morsi HK, Abdulateef NA, Noaman
MK and Abou El-Ella GA: Evaluation of prothrombin induced by
vitamin K absence, macrophage migration inhibitory factor and Golgi
protein-73 versus alpha fetoprotein for hepatocellular carcinoma
diagnosis and surveillance. Scand J Clin Lab Invest. 77:175–183.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dai M, Chen X, Liu X, Peng Z, Meng J and
Dai S: Diagnostic value of the combination of Golgi protein 73 and
alpha-fetoprotein in hepatocellular carcinoma: A meta-analysis.
PLoS One. 10:e01400672015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Waidely E, Al-Yuobi AR, Bashammakh AS,
El-Shahawi MS and Leblanc RM: Serum protein biomarkers relevant to
hepatocellular carcinoma and their detection. Analyst. 141:36–44.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kladney RD, Cui X, Bulla GA, Brunt EM and
Fimmel CJ: Expression of GP73, a resident Golgi membrane protein,
in viral and nonviral liver disease. Hepatology. 35:1431–1440.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang SL, Liu LP, Niu L, Sun YF, Yang XR,
Fan J, Ren JW, Chen GG and Lai PB: Downregulation and pro-apoptotic
effect of hypoxia-inducible factor 2 alpha in hepatocellular
carcinoma. Oncotarget. 7:34571–34581. 2016.PubMed/NCBI
|
|
8
|
Sai W, Wang L, Zheng W, Yang J, Pan L, Cai
Y, Qiu L, Zhang H, Wu W and Yao D: Abnormal expression of Golgi
protein 73 in clinical values and their role in HBV-related
hepatocellular carcinoma diagnosis and prognosis. Hepat Mon.
15:e329182015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bedossa P and Poynard T: An algorithm for
the grading of activity in chronic hepatitis C. The METAVIR
cooperative study group. Hepatology. 24:289–293. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang SL, Ren QG, Zhang T, Pan X, Wen L, Hu
JL, Yu C and He QJ: Hepatitis B virus X protein and
hypoxiainducible factor-1α stimulate Notch gene expression in liver
cancer cells. Oncol Rep. 37:348–356. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wei H, Li B, Zhang R, Hao X, Huang Y, Qiao
Y, Hou J and Li X and Li X: Serum GP73,a marker for evaluating
progression in patients with chronic HBV infections. PLoS One.
8:e538622013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu JL, Liu LP, Yang SL, Fang X, Wen L, Ren
QG and Yu C: Hepatitis B virus induces hypoxia-inducible factor-2α
expression through hepatitis B virus X protein. Oncol Rep.
35:1443–1448. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kladney RD, Bulla GA, Guo L, Mason AL,
Tollefson AE, Simon DJ, Koutoubi Z and Fimmel CJ: GP73, a novel
Golgi-localized protein upregulated by viral infection. Gene.
249:53–65. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kong F, You H, Tang R and Zheng K: The
regulation of proteins associated with the cytoskeleton by
hepatitis B virus X protein during hepatocarcinogenesis. Oncol
Lett. 13:2514–2520. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hou Z, Xu X, Fu X, Tao S, Zhou J, Liu S
and Tan D: HBx-related long non-coding RNA MALAT1 promotes cell
metastasis via up-regulating LTBP3 in hepatocellular carcinoma. Am
J Cancer Res. 7:845–856. 2017.PubMed/NCBI
|
|
16
|
Chen S, Dong Z, Yang P, Wang X, Jin G, Yu
H, Chen L, Li L, Tang L, Bai S, et al: Hepatitis B virus X protein
stimulates high mobility group box 1 secretion and enhances
hepatocellular carcinoma metastasis. Cancer Lett. 394:22–32. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu M, Li W, Lu Y, Dong X, Lin B, Chen Y,
Zhang X, Guo J and Li M: HBx drives alpha fetoprotein expression to
promote initiation of liver cancer stem cells through activating
PI3K/AKT signal pathway. Int J Cancer. 140:1346–1355. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu M, Lu Y, Li W, Guo J, Dong X, Lin B,
Chen Y, Xie X and Li M: Hepatitis B virus X protein driven alpha
fetoprotein expression to promote malignant behaviors of normal
liver cells and hepatoma cells. J Cancer. 7:935–946. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Geis T, Döring C, Popp R, Grossmann N,
Fleming I, Hansmann ML, Dehne N and Brüne B: HIF-2alpha-dependent
PAI-1 induction contributes to angiogenesis in hepatocellular
carcinoma. Exp Cell Res. 331:46–57. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo XF, Wang AY and Liu J:
HIFs-MiR-33a-Twsit1 axis can regulate invasiveness of
hepatocellular cancer cells. Eur Rev Med Pharmacol Sci.
20:3011–3016. 2016.PubMed/NCBI
|
|
21
|
Yuan P, Cao W, Zang Q, Li G, Guo X and Fan
J: The HIF-2α-MALAT1-miR-216b axis regulates multi-drug resistance
of hepatocellular carcinoma cells via modulating autophagy. Biochem
Biophys Res Commun. 478:1067–1073. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee JH, Hur W, Hong SW, Kim JH, Kim SM,
Lee EB and Yoon SK: ELK3 promotes the migration and invasion of
liver cancer stem cells by targeting HIF-1α. Oncol Rep. 37:813–822.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu T, Tang B and Sun X: Development of
inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer
therapy. Yonsei Med J. 58:489–496. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin D and Wu J: Hypoxia inducible factor
in hepatocellular carcinoma: A therapeutic target. World J
Gastroenterol. 21:12171–12178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Keith B, Johnson RS and Simon MC: HIF1α
and HIF2α: Sibling rivalry in hypoxic tumour growth and
progression. Nat Rev Cancer. 12:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
